Nathaniel Calloway's most recent trade in Anebulo Pharmaceuticals Inc was a trade of 25,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on April 4, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Anebulo Pharmaceuticals Inc | Nathaniel Calloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
Anebulo Pharmaceuticals Inc | Nathaniel Calloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2025 | 3,309 | 3,309 | - | - | Stock Option (right to buy) | |
Lifecore Biomedical Inc | Nathaniel Calloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2024 | 30,000 | 58,069 (0%) | 0% | - | Common Stock | |
Anebulo Pharmaceuticals Inc | Nathaniel Calloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 41,667 | 41,667 | - | - | Stock Option (right to buy) | |
Anebulo Pharmaceuticals Inc | Nathaniel Calloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 1,655 | 1,655 | - | - | Stock Option (right to buy) |